Accelera

What Accelera does

Accelera S.r.l. is a preclinical contract research organization (CRO) headquartered in Nerviano, Greater Milan, Italy, founded in 2009 as the independent CRO unit of Nerviano Medical Sciences (NMS). The company operates from a single site with more than 60 years of pharmaceutical R&D heritage tracing from Farmitalia's pioneering anthracycline research through Pharmacia, Pfizer, and NMS. Accelera delivers GLP-compliant preclinical services across general toxicology, safety pharmacology, developmental and reproductive toxicology (DART), genetic toxicology, carcinogenicity studies, efficacy modeling, biomarker analysis, formulation development, and regulatory consulting, supporting small molecules, biologics, biosimilars, oligonucleotides, and advanced cell and gene therapies from discovery through marketing authorization. Its facilities hold GLP certification and AAALAC accreditation, with data accepted by EMA, FDA, KFDA, and MHLW for regulatory submissions.

The company's service portfolio is organized into three pillars: Drug Development Services spanning Discovery, IND-Enabling, and Post-IND phases; Research Models including over 50 validated cell line-derived xenograft (CDX), syngeneic, humanized, orthotopic, bioluminescent, and genetically modified mouse models; and operational capabilities including SEND data generation, anatomic and clinical pathology, project management, GLP-compliant archiving, and safety/regulatory strategy. Notable technical components include validated ELISA and multiplex immunoassay biomarker platforms, integrated telemetry platforms for cardiovascular, pulmonary, and nervous system safety assessments, and IVIS-based bioluminescent imaging for orthotopic models. Accelera has completed over 100 GLP-compliant DART studies since 2010 and serves more than 300 pharmaceutical and biotechnology customers in Europe, the US, and South Korea.

Accelera operates a fee-for-service business model with custom quote-based pricing and multi-year contract structures, generating revenue through fee-for-service contract research agreements rather than product sales. Its go-to-market combines direct enterprise sales, inside sales through website inquiries, strategic partnering programs, and active participation at major industry events including BIO Europe, BIO International Convention, Swiss Biotech Day, BioTrinity, LSX Nordic Congress, German Biotech Days, NLS Days, and BIO-Europe Spring. The company targets large pharmaceutical enterprises alongside resource-constrained small biotechs, startups, and academic institutions. Accelera is a wholly-owned subsidiary of NMS Group S.p.A. with no disclosed external institutional or venture capital backing.

Name

Accelera

Legal name

Accelera S.r.l.

Website

https://accelera.org

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Accelera is a Milan-based preclinical CRO specializing in GLP-compliant toxicology, safety pharmacology, DART studies, and oncology efficacy models. It serves over 300 pharmaceutical and biotechnology companies globally, supporting drug development from discovery through marketing authorization across small molecules, biologics, and advanced therapies.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Preclinical toxicology
• Safety pharmacology
• IND-enabling studies
• Developmental reproductive toxicology
• Oncology efficacy models

Headquarters

HQ city

Nerviano

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services: Accelera generates revenue through fee-for-service contract research agreements providing preclinical toxicology, safety pharmacology, efficacy studies, and regulatory consulting services to pharmaceutical and biotech companies. Services range from early discovery through IND-enabling packages to post-IND programs for marketing authorization.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Accelera is a Contract Research Organization (CRO) that provides integrated preclinical drug development services from early discovery through IND-enabling studies and post-IND programs. Its portfolio covers general and specialized toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), carcinogenicity studies, efficacy models for oncology, bioanalytical/biomarker analysis, formulation development, and regulatory consulting. Services are delivered under GLP and AAALAC standards recognized by EMA, FDA, KFDA, and MHLW, supporting small molecules, biologics, biosimilars, oligonucleotides, and advanced cell and gene therapies.

Product overview

Accelera is a premium-tier Contract Research Organization (CRO) based in Milan, Italy, providing integrated preclinical drug development services. The company's portfolio spans three core areas: Drug Development Services (encompassing Discovery, IND-Enabling, and Post-IND phases), Research Models (including CDX, Syngeneic, Humanized, Orthotopic/Bioluminescent, and Genetically Modified models), and Capabilities (Scientific, Strategic, and Operational). Services include general toxicology, DART studies, safety pharmacology, genetic toxicology, biomarkers, efficacy models, formulation development, and regulatory consulting. The integrated platform supports small molecules, biologics, and advanced therapies (cell and gene therapy) from early discovery through marketing authorization, serving over 300 global pharmaceutical and biotechnology companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Target Safety Assessment Structured evaluation of biological safety profiles of drug targets early in discovery, combining literature review, genetic and pathway analysis, and translational insight to identify potential safety risks before program progression.

Quantifiable outcome

• >100 GLP-compliant DART studies completed since 2010
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• DNDi (Drugs for Neglected Diseases initiative)coreStrategic or Co-development PartnerKey partnership with DNDi, an international non-profit drug research and development organization, to advance treatments for neglected diseases. Accelera provides preclinical expertise as part of collaborative efforts to develop new therapies.
• CellectiscoreStrategic or Co-development PartnerPartnership with Cellectis, a clinical-stage biopharmaceutical company focused on oncology, leveraging Accelera's preclinical capabilities for advanced therapy development.
• Karolinska InstitutetcoreStrategic or Co-development PartnerCollaborative partnership with Karolinska Institutet, one of Europe's largest and most prestigious medical universities, for research and development initiatives in drug discovery and development.
• NMS Group S.p.A.coreOthersAccelera Srl is part of NMS Group S.p.A. along with Nerviano Medical Sciences S.r.l., NerPharMa S.r.l., and SIMIS S.r.l. The NMS Group provides direction and control, with Accelera operating as the CRO unit offering third-party preclinical services.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• ICON plc: Global CRO with preclinical and clinical safety capabilities through acquisitions. While primarily clinical, ICON's preclinical safety and laboratory services overlap with Accelera's offerings for integrated sponsors.
• Eurofins Scientific: Large testing and CRO group with preclinical safety and toxicology service lines in Europe. Competes with Accelera for European biotech preclinical work, particularly for sponsors seeking broad lab services alongside toxicology.
• WuXi AppTec: Global CRO/CDMO offering preclinical toxicology and safety assessment as part of a broader integrated discovery-to-manufacturing platform. Competes with Accelera on preclinical study execution, particularly for biotech clients seeking integrated services.
• Labcorp Drug Development (formerly Covance): Major CRO providing preclinical toxicology and safety assessment services alongside broad clinical and central lab offerings. Direct competitor for preclinical safety work, with substantially larger scale and global footprint.
• Charles River Laboratories: Global CRO with a leading preclinical and safety assessment division that competes with Accelera in GLP toxicology, DART, and safety pharmacology. Far larger and broader, but Accelera competes on boutique attention and specialty oncology/advanced-therapy expertise.

Direct peers

• Inotiv: Preclinical CRO focused on toxicology, safety assessment, and research models, with a similar specialized niche to Accelera including DART and safety pharmacology capabilities. Highly relevant direct competitor for boutique preclinical services.
• Celerion: Specialized CRO offering preclinical and early clinical services including bioanalytical and clinical pharmacology. Comparable in scale and boutique positioning to Accelera, particularly attractive to small biotech sponsors.
• Toxikon: Preclinical CRO specialized inGLP toxicology, medical device, and pharmaceutical safety studies. Comparable boutique CRO competing with Accelera in preclinical safety assessment, particularly for North American sponsors.
• SGS Life Sciences: Global CRO offering preclinical toxicology, safety pharmacology, and bioanalytical services with GLP accreditation. Highly comparable to Accelera in service mix and customer base, particularly in European preclinical safety.

Emerging players

• Pharmaron: Integrated CRO/CDMO with growing preclinical toxicology and safety assessment capabilities in the UK, China, and US. Overlaps with Accelera on preclinical services and competes for biotech and emerging pharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/accelera-srl

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelera